Metabolism and Metabolomics of Liver in Health and Disease

• Format: eBook
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Subjects: Medicine and Nursing; 1H-NMR spectroscopy; acetaminophen; acupuncture; alcoholic liver disease; arachidonic acid; bile acids; biomarker; blood; carbohydrate response element-binding protein; cells; cholestasis; ChREBP; cirrhosis; de novo lipogenesis; diabetes; docosahexaenoic acid; feces; fibrosis; Fibrosis; GC-MS; Genomics; glucose homeostasis; glucose production; glycogen; glycogen storage disease type I; glycolysis; heat stress; HepaRG; hepatotoxicity; hexosamine; imflammation; in vitro; inflammation; lipid homeostasis; lipid metabolism; lipidomics; liquid chromatography; liquid chromatography-mass spectrometry; liver; Liver biopsy; liver function; mass spectrometry; metabolic pathway; metabolic profile; metabolic stress; metabolomics; Metabolomics; metabolomics quantitative profiling; multivariate statistical analysis; NAFL; NAFLD; NASH; nicotinamide; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; nonalcoholic fatty liver; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; nuclear magnetic resonance spectroscopy; oxidative stress; pentose phosphate pathway; premalignant; primary mouse hepatocytes; Proteomics; rat plasma; reference toxicants; sodium saccharin; standard operating procedures; steatosis; tandem mass spectrometry; tissue; transcription factors; Transcriptomics; urine
• Online Access: Open Access: DOAB: description of the publication; Open Access: DOAB, download the publication

 Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.